Gossamer bio announces first quarter 2024 financial results and provides business update

San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah) and pulmonary hypertension associated with interstitial lung disease (ph-ild), today announced its financial results for the first quarter ended march 31, 2024, and provided a business update. “our team at gossamer continues to execute on our mission to enhance the live.
GOSS Ratings Summary
GOSS Quant Ranking